Aarvik Therapeutics, Inc. Overview
Pro stress-test →Aarvik Therapeutics is a biotech company building novel therapeutics for oncology using its proprietary next generation MUTTA™ Antibody Drug Conjugate platform. Founded in 2020, the company leverages advanced protein engineering to develop cancer therapies with improved therapeutic windows.
Strategic Profile
Pro stress-test →Aarvik developed its proprietary MUTTA™ (MUlti-epitope Targeting Tetravalent Antibody) platform focused on developing next generation antibody drug conjugates (ADCs) that can expand the success of ADCs beyond a limited number of targets, facilitating the lowering of the minimum effective dose (MED) while maintaining or improving the maximum tolerated dose (MTD), thereby significantly improving the therapeutic window. The company employs a partner-centric model, demonstrating validation through licensing agreements with clinical-stage partners.
Competitive Landscape
Pro stress-test →Aarvik competes in the antibody-drug conjugate (ADC) space alongside established players and emerging biotechs. The ADC field has seen substantial investment and multiple FDA approvals. Aarvik's modular MUTTA™ platform differentiates by enabling multi-target engagement to improve therapeutic indices on difficult oncology targets where prior-generation ADCs underperformed or failed. Competition includes both large pharma developing next-generation ADCs and other platform biotech companies.
Industry Context
Aarvik Therapeutics, Inc. operates in Antibody-drug conjugate (ADC) therapeutics.
Key facts
Founded: 2020 · Headquarters: Hayward, US · Employees: 11